Reuters Health Report

If you are having trouble viewing this email or would like to view it in your web browser, CLICK HERE

Good Morning Postlinuxeg, THU 27 May 2010 
 
AIDS funding squeeze puts lives at risk
Herbs, supplements often sold deceptively: U.S. report
Pfizer halts heart failure trial early for benefit
Nosebleed won't stop? Coil surgery might help
Drug cocktails cut couples' HIV transmission risk
Peregrine drug shows promise against breast cancer
Sanofi prostate cancer drug shows 28 percent survival
FDA probes hundreds of problems with J&J medicines
U.S. gene study reveals toll of heavy smoking
No race disparity seen in IVF using frozen embryos

AIDS funding squeeze puts lives at risk
May 27, 2010 09:40 AM ET
(Official correction by Medecins San Frontieres to remove Germany from paragraph 9)

Full Article
Herbs, supplements often sold deceptively: U.S. report
May 26, 2010 04:05 PM ET
WASHINGTON (Reuters) - Sellers of ginseng, echinacea and other herbal and dietary supplements often cross the line in marketing their products, going as far as telling consumers the pills can cure cancer or replace prescription medications, a U.S. government probe found.

Full Article
Pfizer halts heart failure trial early for benefit
May 27, 2010 07:20 AM ET
NEW YORK (Reuters) - Pfizer Inc said on Thursday it is halting recruitment of patients into a heart failure clinical study involving its drug Inspra because the study reached its main efficacy goal early.

Full Article
Nosebleed won't stop? Coil surgery might help
May 27, 2010 10:04 AM ET
NEW YORK (Reuters Health) - A small study suggests that a surgical treatment generally used on patients with tumors and certain brain disorders may put a stop to nosebleeds that won't stop any other way.

Full Article
Drug cocktails cut couples' HIV transmission risk
May 26, 2010 06:37 PM ET
CHICAGO (Reuters) - In a study that supports the widespread use of drugs to help control the AIDS pandemic, researchers said on Wednesday that HIV patients who took the drugs were far less likely to infect their partners.

Full Article
Peregrine drug shows promise against breast cancer
May 27, 2010 07:51 AM ET
LOS ANGELES (Reuters) - A small, mid-stage trial of an experimental breast cancer drug developed by Peregrine Pharmaceuticals Inc showed that 74 percent of patients responded to the treatment, according to the company.

Full Article
Sanofi prostate cancer drug shows 28 percent survival
May 27, 2010 03:09 AM ET
PARIS (Reuters) - Sanofi-Aventis' cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.

Full Article
FDA probes hundreds of problems with J&J medicines
May 26, 2010 10:24 AM ET
WASHINGTON (Reuters) - U.S. health regulators are investigating hundreds of reported complications with dozens of recalled children's medications made by Johnson & Johnson, including 30 deaths, but so far no direct link has been found, according to a congressional report.

Full Article
U.S. gene study reveals toll of heavy smoking
May 26, 2010 04:04 PM ET
CHICAGO (Reuters) - Heavy smokers who get lung cancer may have tens of thousands of genetic mutations, U.S. researchers said on Wednesday.

Full Article
No race disparity seen in IVF using frozen embryos
May 26, 2010 05:27 PM ET
NEW YORK (Reuters Health) - Using frozen embryos may level the playing field for African-American and white women undergoing in vitro fertilization, a new study suggests, despite earlier research showing that African- American women have lower success rates with the procedure than white women do.

Full Article
 
 











REUTERS www.reuters.com
Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book.Details
Subscribe to other Reuters newsletters
Unsubscribe from this newsletter.


Forward to a friend Send this mailing to a friend or colleague


Reuters.com: Help and Contact Us | Advertise With Us | Mobile | Newsletters | RSS RSS Feed | Interactive TV | Labs | Reuters in Second Life | Archive | Site Index | Video Index

Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers

0 comentários: